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Among 144 ciprofloxacin-resistant Escherichia coli isolated in Brazil, one (0.69%) QnrA1-producing isolate
was detected. The qnrA1 gene was associated with ISCR1. The QnrA1 determinant was carried on a 41-kb
conjugative plasmid, which also carried a FOX-type cephalosporinase encoding gene and a class 1 integron
with the aadB and catB3 cassettes. This is the first report of a qnrA-carrying isolate in a Latin American
country.
The quinolone resistance gene (qnr) was first isolated from
an extended-spectrum -lactamase-producing Klebsiella pneu-
moniae strain in Birmingham, AL, in 1998 (4). Since qnrA was
characterized, these genes have been reported in E. coli and K.
pneumoniae from different regions (5, 8). Recently, a new
qnr-type, qnrB, was described in a K. pneumoniae strain and in
other members of the Enterobacteriaceae (10). QnrB showed
less than 40% amino acid identity with QnrA. Environmental
species have been speculated as the likely source of qnr-type
determinants (8). The qnr gene has been mostly carried by
conjugative plasmids that carry other resistance genes as well
(8, 10). Thus, the spread of qnrA is worrisome because it could
jeopardize not only the future clinical use of fluoroquinolones
but also the use of other unrelated antimicrobial compounds.
From January 2002 to June 2003, a total of 144 ciprofloxa-
cin-resistant Escherichia coli (MIC, 4 g/ml) were isolated
from 17 hospital-based laboratories throughout Brazil. Only
one isolate per patient was included in the study. A summary
description of the demographic data, such as the patient’s
initials, age, gender, hospitalization ward, and underlying con-
ditions, was obtained. The molecular characterization of these
isolates by pulsed-field gel electrophoresis showed a great
genomic diversity (data not shown).
All isolates were screened for qnrA by colony blotting and
hybridization methods as previously described (13). The qnrA
probe was synthesized from a K. pneumoniae strain harboring
plasmid pMG252 (4) by PCR with the primers QNRF and
QNRR (Table 1). Of the 144 strains, only one qnrA-carrying
isolate (strain 13.52) was detected (0.69%). Strain 13.52 was
isolated from a urinary specimen of an 80-year-old female who
was hospitalized in Porto Alegre, Brazil. This isolate showed
resistance to most -lactams (except cefepime and carbapen-
ems), all quinolones tested, streptomycin, and chlorampheni-
col (Table 2) (1). In contrast, this strain was susceptible to
gentamicin (MIC, 2 g/ml), and amikacin (MIC, 4 g/ml).
PCR amplification and DNA sequencing were performed
with the primers listed in Table 1. The amplicons obtained with
PCRs were sequenced on both strands using the ABI Prism
377 system (Applied Biosystems, Foster City, CA). The nucle-
otide sequences were analyzed by using the Lasergene software
package (DNASTAR, Madison, WI), and the sequences ob-
tained were compared to sequences available over the internet
(http://www.ncbi.nlm.nih.gov/BLAST/).
Investigation of amplicons obtained with primers for qnr and
adjacent structures demonstrated that strain 13.52 harbored
the same qnrA1 that was originally identified in the plasmid
pMG252 carried by a K. pneumoniae strain from Birmingham,
AL (GenBank accession number AY070235) (4). DNA se-
quences produced by further PCR and sequencing experiments
assembled a 3,942-bp contiguous sequence (GenBank acces-
sion number AM295981). Analysis of this sequence revealed
that qnrA was located in a sul1-type integron structure and was
embedded downstream of a putative recombinase sequence,
orf513, known as common region 1 (ISCR1) (11). The quino-
lone resistance gene was located immediately upstream of a
truncated version of qacE1/sul1. This element showed 100%
homology to the sul1-type integron structure identified in
pMG252 (GenBank accession number DQ831140) (7).
Amplification experiments using primers targeting the con-
served regions of class 1 integrons (integrase encoding gene
and qacE1/sul1) detected a 2.0-kb integron (GenBank acces-
sion number AM295980) in the strain 13.52. A walking se-
quencing strategy revealed two gene cassettes in the variable
region of this integron, aadB and catB3, encoding resistance to
aminoglycosides and chloramphenicol, respectively. This inte-
gron was identical to In-t1 carried by a Salmonella enterica
serotype Typhimurium strain isolated from the stool of an
infant hospitalized due to acute gastroenteritis at a university
hospital in Tirana, Albania (12). Attempts to link the qnrA
structure to the integron described above using long-extension
PCRs with primers annealing in different positions of the vari-
able region of the class 1 integron and qnrA1 failed, suggesting
that these two structures were separate.
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Mating experiments were carried out in liquid medium using
a streptomycin-resistant E. coli J53 derivative strain. Transcon-
jugants were selected on agar plates containing 10 g of chlor-
amphenicol/ml and 1,000 g of streptomycin/ml. The presence
of the qnrA and catB3 genes in the selected transconjugants
was confirmed by PCR and sequencing with specific primers,
showing that both genes were present in the colonies obtained
by conjugation. The J53-13.52 strain showed higher fluoro-
quinolone MICs (Table 2) than previously reported for qnrA
transconjugants (fluoroquinolone MICs ranging from 0.25 to 1
g/ml) (9). Due to this fact, ciprofloxacin, gatifloxacin, and
levofloxacin MICs were confirmed by agar dilution according
to the method of the Clinical and Laboratory Standards Insti-
tute (1). Sequencing of the gyrA and parC quinolone resistance
determining regions, performed as previously described (3),
revealed that these regions were identical in the donor, recip-
ient, and transconjugant strains and did not contain mutations
associated with quinolone resistance.
Mechanisms such as overexpression of the Acr efflux system
and alteration in the outer membrane permeability were un-
likely to contribute to the high fluoroquinolone resistance lev-
els exhibited by the strain 13.52 and its transconjugant (4) since
these mechanisms are chromosomally mediated and could not
be transferred. In addition, the MICs for ciprofloxacin and
nalidixic acid were not affected in the presence of the pump
inhibitors, phenyl-arginine--naphthylamide, and reserpine (6;
data not shown). Moreover, the outer membrane protein pro-
file (2) was determined for the clinical (13.52), recipient (E.
coli J53), and transconjugant strains. The profiles of the recip-
ient and transconjugant J53-13.52 strains were identical (data
not shown).
The high fluoroquinolone resistance level observed in the
strain 13.52 and its transconjugant J53-13.52 could possibly be
attributed to the association of qnrA1 and a gene encoding the
quinolone- and aminoglycoside-modifying enzyme AAC(6)-
Ib-cr, as recently described (9). However, PCR with primers
targeting this resistance determinant failed to yield positive
results with both strain 13.52 and its transconjugant J53-13.52.
These results are in accordance with the amikacin susceptibil-
ity profile of the strain 13.52 and its transconjugant. Usually,
AAC(6)-Ib-cr-producing isolates are resistant to this com-
pound as well as to kanamycin and tobramycin (9).
The mechanism of higher fluoroquinolone resistance con-
ferred by the plasmid carried by strain 13.52, compared to that
conferred by other Qnr-encoding plasmids (8. 10), could be
attributed to a higher expression of qnrA1 due to a higher
plasmid copy number and/or to another yet-unknown plasmid-
mediated resistant determinant. Further studies are under way
to clarify this issue.
Since several -lactamase genes have been found on qnrA-
carrying plasmids (8, 10) and -lactam resistance was trans-
ferred along with quinolone resistance to the transconjugant
strain, the presence of -lactamases was investigated in strain
13.52 and its transconjugant. The phenotypic detection of ex-
tended-spectrum -lactamase using clavulanic acid was per-
formed (1). No reduction in the ceftazidime MIC was observed
in the presence of clavulanic acid. Primers for the genes en-
coding some plasmid-encoded class C -lactamases, namely,
the CMY, DHA, and FOX types, were used to screen for the
presence of these genes by PCR (Table 1). PCR results and
partial sequencing showed that the strain 13.52 and its
transconjugant carried a blaFOX-5-like -lactamase gene. No-
tably, blaFOX-5 was also detected in plasmid pMG252 (10).
Analysis of the plasmid content of the strain 13.52 and the
transconjugant J53-13.52 was evaluated by electrophoresis on
0.8% agarose gel of the cleaved and intact plasmid preparation
performed with a QIAGEN MIDI kit (QIAGEN, Hilden, Ger-
many). According to the HindIII restriction profile, this strain
TABLE 1. Primers used for PCR and sequencing experiments
in this study
Primer Sequence (5–3) GenBankaccession no.
QNR-F GATAAAGTTTTTCAGCAAGAGG AY070235
QNR-R ATCCAGATCGGCAAAGGTTA AY070235
qnrFR ATGGGCTCAGATCTCAGC AY070235
qnrFF CTGATAAAAGCGGCAGCG AY070235
INTI1F CCGTAGAAGAACAGC AJ620678
att1 GCCTGTTCGGTTCGTAAGCT AJ620678
QACR GTTGCGATTACTTCG AJ620678
QacFR AGAGATGAGGGTTCGTTGCAAG AY655485
sul1F CTCACCGAGGACTCCTTC AY655485
sul1FF ACGTGCTGTCGAACCTTC AY655485
sul1FR GAAGGAGTCCTCGGTGAG AY655485
aadBFF TTTCAGGTCGCGATATGC AJ009818
aadBR AGACCTCAACCTTTTCCG AJ009818
catB3F TCAGAGTAGGCCGGTATAGC AJ009818
catB3R CGCCAATACTTATGCAGACC AJ009818
catB3FF ACAATGCCTCTGCTGTGCTC AJ009818
catB3FR AGCTATACCGGCCTACTCTG AJ009818
CRF CACT(A/T)CCACATGCTGT(G/T)(G/T)C AY070235
CRR CGCTTGAG(G/C)CGTTGC(A/G)(C/T)CC AY070235
CR1FF ACATGGACCAGGCTCAATTGTG AY070235
CR1-FR GCGACTTTCAACGCCATC AY070235
DHA-1F CACTGATTTCCGCTCTGC AJ237702
DHA-1R AGCCTGTGCAGCTTTGAC AJ237702
CMY-1R CCAACTGCGCCAGGATG X92508
CMY-1F CGACAATCCATCCTGTGG X92508
CMY-2R GGACAGGGTTAGGATAGC X91840
CMY-2F TCGTTATGCTGCGCTCTG X91840
FOX-GenF ATGCAACAACG(A/G)CGTGC X77455
FOX-GenR TCACTCGGCCAACTGACTCAG X77455
aacA4F TGCGATGCTCTATGAGTGGC DQ303918
aacA4R ATGTACACGGCTGGACCATC DQ303918
TABLE 2. Susceptibility to selected antimicrobial agents of the
qnrA donor (13.52), transconjugant (J53-13.52), and recipient
(E. coli J53) strains
Antimicrobial agent
MIC (g/ml) for:
Isolate 13.52 TransconjugantJ53-13.52 E. coli J53
Nalidixic acid 256 128 4
Ciprofloxacin 8 2.0 0.047
Levofloxacin 8 1.5 0.064
Gatifloxacin 8 1.0 0.012
Ampicillin 256 256 8
Ampicillin/sulbactam 32/16 32/16 4/2
Piperacillin-tazobactam 32 16 2
Cefoxitin 32 256 8
Ceftriaxone 8 8 0.047
Ceftazidime 64 128 0.25
Cefepime 0.5 0.5 0.06
Imipenem 0.025 0.025 0.025
Meropenem 0.025 0.025 0.025
Gentamicin 2 2 0.125
Amikacin 4 2 2
Kanamycin 32 128 8
Streptomycin 192 1,024 1,024
Chloramphenicol 256 48 8
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carried a single plasmid of approximately 41 kb (data not
shown).
This is the first report of QnrA-producing E. coli strain in
Brazil and Latin America and highlights the potential of plas-
mid-mediated fluoroquinolone resistance genes such as qnrA1.
The sequences determined in the present study are listed
under GenBank accession numbers AM295981 for the qnrA-
carrying sul1-type element and AM295980 for the copy of
In-t1.
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